Abstract
We have previously published benefits of testosterone therapy (TTh) on cardiometabolic risk factors over 8 years. To study effectiveness and safety of depot injections of testosterone undecanoate (TU) in a urological setting in comparison to an untreated hypogonadal control group. At time of analysis, 823 men with hypogonadism participated in a registry study established in 2004. 428 men received parenteral TU 1000 mg/12 weeks following an initial 6-week interval (T-group) for up to 11 years, 395 men decided against TTh and served as controls (CTRL). Measurements were performed 1-4 times a year for approximately 7,116 patient-years. Mean changes over time between groups were compared by mixed effects model for repeated measures with random effect for intercept and fixed effects for time, group and their interaction and adjusted for age, weight, waist circumference, fasting glucose, blood pressure, lipids, and quality of life scale AMS to account for baseline differences between groups.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
